Takeda Pharmaceutical Company Ltd
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 1925-01-01
- Employees
- -
- Market Cap
- $47.5B
- Website
- http://www.takeda.co.jp/
Pharmacokinetics and Pharmacodynamics Study of Alogliptin in Healthy Korean Participants
- First Posted Date
- 2011-07-12
- Last Posted Date
- 2013-03-22
- Lead Sponsor
- Takeda
- Target Recruit Count
- 48
- Registration Number
- NCT01391663
VELVET, a Dose Range Finding Trial of Veltuzumab in Subjects With Moderate to Severe Rheumatoid Arthritis
- First Posted Date
- 2011-07-11
- Last Posted Date
- 2016-04-13
- Lead Sponsor
- Takeda
- Target Recruit Count
- 300
- Registration Number
- NCT01390545
- Locations
- 🇬🇧
Nycomed Investigational Site, Barnsley, S. Yorkshire, United Kingdom
Study of TAK-816 in Healthy Infants
Phase 3
Completed
- Conditions
- Immunization
- Interventions
- Biological: ActHIB+ DPT-TAKEDABiological: TAK-816+ DPT-TAKEDA
- First Posted Date
- 2011-06-23
- Last Posted Date
- 2013-03-05
- Lead Sponsor
- Takeda
- Target Recruit Count
- 416
- Registration Number
- NCT01379846
Vortioxetine (Lu AA21004) 10 and 20 mg for Treatment of Major Depressive Disorder With Sexual Dysfunction
Phase 3
Completed
- Conditions
- Treatment Outcome
- Interventions
- First Posted Date
- 2011-06-02
- Last Posted Date
- 2014-10-09
- Lead Sponsor
- Takeda
- Target Recruit Count
- 447
- Registration Number
- NCT01364649
TASALL - TachoSil® Against Liquor Leak
Phase 3
Completed
- Conditions
- Cerebrospinal Fluid Leaks
- Interventions
- Procedure: TachoSil®Procedure: Current Practice
- First Posted Date
- 2011-05-18
- Last Posted Date
- 2014-07-25
- Lead Sponsor
- Takeda
- Target Recruit Count
- 726
- Registration Number
- NCT01355627
- Locations
- 🇸🇪
Nycomed Investigational Site, Stockholm, Sweden
Efficacy Study of Vortioxetine (Lu AA21004) for Treatment of Major Depressive Disorder
- First Posted Date
- 2011-05-17
- Last Posted Date
- 2014-11-11
- Lead Sponsor
- Takeda
- Target Recruit Count
- 366
- Registration Number
- NCT01355081
Long-term Efficacy and Safety Study of TAK-085 in Participants With Hypertriglyceridemia
Phase 3
Completed
- Conditions
- Hypertriglyceridemia
- Interventions
- Drug: omega-3-acid ethyl esters 90 (TAK-085)Drug: Eicosapentaenoic acid-ethyl (EPA)
- First Posted Date
- 2011-05-10
- Last Posted Date
- 2016-09-20
- Lead Sponsor
- Takeda
- Target Recruit Count
- 503
- Registration Number
- NCT01350999
Efficacy of TAK-085 in Participants With Hypertriglyceridemia
Phase 3
Completed
- Conditions
- Hypertriglyceridemia
- Interventions
- Drug: Omega-3-acid ethyl esters 90 (TAK-085)Drug: Eicosapentaenoic acid-ethyl (EPA-E)
- First Posted Date
- 2011-05-10
- Last Posted Date
- 2016-09-20
- Lead Sponsor
- Takeda
- Target Recruit Count
- 611
- Registration Number
- NCT01350973
Long-term Safety Study of Alogliptin Used in Combination With Sulfonylurea or Metformin in Participants With Type 2 Diabetes in Japan
Phase 2
Completed
- Conditions
- Type 2 Diabetes Mellitus
- Interventions
- First Posted Date
- 2011-03-18
- Last Posted Date
- 2012-08-16
- Lead Sponsor
- Takeda
- Target Recruit Count
- 576
- Registration Number
- NCT01318135
Long-term Safety Study of Alogliptin Used in Combination With Thiazolidine in Participants With Type 2 Diabetes in Japan
- First Posted Date
- 2011-03-18
- Last Posted Date
- 2012-02-03
- Lead Sponsor
- Takeda
- Target Recruit Count
- 336
- Registration Number
- NCT01318122
© Copyright 2025. All Rights Reserved by MedPath